Trial Profile

Phase 2 Safety and Efficacy Study Evaluating Glutamic Acid Decarboxylase Gene Transfer to Subthalamic Nuclei in Subjects With Advanced Parkinson's Disease

Status: Discontinued

Phase of Trial: Phase II

Latest Information Update: 22 Dec 2018

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs NLX P101 (Primary)
Indications Parkinson's disease
Focus Adverse reactions; Therapeutic Use
Sponsors Neurologix

Most Recent Events

12 Dec 2018 Results presented in a MeiraGTx media release.
12 Dec 2018 According to a MeiraGTx media release, results from this study were published in the 2018 issue of Science Translational Medicine.
09 Oct 2018 According to a MeiraGTx media release, results of this trial were published in the August 2014 issue of Journal of Clinical Investigation and the April 2017 issue of JCI Insight.

You need to be a logged in or subscribed to view this content Request demo (opens in a new window)

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com